MARLBOROUGH, Mass. — Hologic, Inc. said Chief Executive Officer Steve MacMillan will retire upon the completion of the company’s planned go-private transaction with Blackstone and TPG, expected to close around April 7, 2026.
The company said all required regulatory approvals for the transaction have been secured.
“Hologic’s board of directors, and all the Company’s stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry,” said Amy Wendell, Hologic’s lead independent director. “He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us through a successful go-private transaction.”
MacMillan has led Hologic for more than 12 years, during which the company reported a 65% increase in revenue, a 184% rise in non-GAAP earnings per share, and a 241% gain in share price. The company’s workforce also expanded by more than 1,500 employees during his tenure.
“Leading Hologic has been the greatest honor and privilege of my career,” MacMillan said. “I’m immensely grateful to the customers and patients who trusted us, the board and investors who supported us, and especially the employees who made all our accomplishments possible. I know they will make even greater contributions to women’s health as a private firm owned by Blackstone and TPG.”
Hologic said it expects to announce MacMillan’s successor when the transaction is completed.
MacMillan, 62, joined Hologic as President and CEO in December 2013 and was named chairman in 2015. Prior to Hologic, he served as President and CEO of Stryker from 2005 to 2012 and held senior roles at Pharmacia and Johnson & Johnson. He began his career at Procter & Gamble in 1985. He holds a bachelor’s degree in economics from Davidson College and completed the advanced management program at Harvard Business School.
